Z. Végh

A. Bitton, P. Lakatos, W. Afif, 2018, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Disease course of inflammatory bowel disease unclassified in a European population‐based inception cohort: An Epi‐IBD study

V. Andersen, L. Kupčinskas, S. Sebastian, 2019, Journal of gastroenterology and hepatology.

Vitamin D deficiency in a European inflammatory bowel disease inception cohort: an Epi-IBD study

C. O'Morain, V. Andersen, L. Kupčinskas, 2018, European journal of gastroenterology & hepatology.

Therapeutic preferences and outcomes in newly diagnosed patients with Crohn’s diseases in the biological era in Hungary: a nationwide study based on the National Health Insurance Fund database

P. Lakatos, Z. Végh, P. Golovics, 2018, BMC Gastroenterology.

Occurrence of Anaemia in the First Year of Inflammatory Bowel Disease in a European Population-based Inception Cohort—An ECCO-EpiCom Study

C. O'Morain, V. Andersen, L. Kupčinskas, 2017, Journal of Crohn's & colitis.

The epidemiology of inflammatory bowel diseases from West to East

P. Lakatos, Z. Végh, Z. Kurti, 2017 .

Nationwide prevalence and drug treatment practices of inflammatory bowel diseases in Hungary: A population-based study based on the National Health Insurance Fund database.

P. Lakatos, K. Gecse, Z. Végh, 2016, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Treatment Steps, Surgery, and Hospitalization Rates During the First Year of Follow-up in Patients with Inflammatory Bowel Diseases from the 2011 ECCO-Epicom Inception Cohort.

P. Lakatos, P. Munkholm, E. Langholz, 2015, Journal of Crohn's & colitis.

Novel Drug Therapies for the Treatment of Crohn's Disease

P. Lakatos, P. Miheller, Z. Végh, 2015 .

Incidence and initial disease course of inflammatory bowel diseases in 2011 in Europe and Australia: results of the 2011 ECCO-EpiCom inception cohort.

L. Kupčinskas, P. Lakatos, P. Munkholm, 2014, Journal of Crohn's & colitis.

Health care and patients' education in a European inflammatory bowel disease inception cohort: an ECCO-EpiCom study.

C. O'Morain, E. Björnsson, V. Andersen, 2014, Journal of Crohn's & colitis.

Generation of tumor cell lysate-loaded dendritic cells preprogrammed for IL-12 production and augmented T cell response

A. Mazumder, Z. Végh, 2003, Cancer Immunology, Immunotherapy.

Infliximab biosimilar CT-P13 therapy is effective and safe in maintaining remission in Crohn’s disease and ulcerative colitis – experiences from a single center

K. Farkas, F. Nagy, T. Molnár, 2017, Expert opinion on biological therapy.

Levels of anti-double-strained DNA but not antinuclear antibodies are associated with treatment efficacy and adverse outcomes in Crohn's disease patients treated with anti-TNFα.

K. Farkas, T. Molnár, M. Papp, 2013, Journal of gastrointestinal and liver diseases : JGLD.

Tuberculin Skin Test and Quantiferon in BCG Vaccinated, Immunosuppressed Patients with Moderate-to-Severe Inflammatory Bowel Disease.

K. Farkas, T. Molnár, P. Lakatos, 2015, Journal of gastrointestinal and liver diseases : JGLD.

Optimizing Patient Management in Crohn's Disease in a Tertiary Referral Center: the Impact of Fast-Track MRI on Patient Management and Outcomes.

P. Lakatos, G. Rudas, Z. Végh, 2018, Journal of gastrointestinal and liver diseases : JGLD.

Infliximab biosimilar CT-P13 therapy is effective in maintaining endoscopic remission in ulcerative colitis – results from multicenter observational cohort

K. Farkas, F. Nagy, T. Molnár, 2018, Expert opinion on biological therapy.

Increased expression of MHC class I molecules on human cells after short time IFN-γ treatment

E. Klein, Z. Végh, F. Vánky, 1993 .

Assembly of MHC class I molecules in ex vivo carcinoma cells induced by IFN-gamma or by a binding peptide.

E. Klein, U. Persson, Z. Végh, 1992, Cellular immunology.

Adenomatous polyps in ulcerative colitis and colonic Crohn’s disease: less frequent, but does this change surveillance strategy?

P. Lakatos, Z. Végh, Z. Kurti, 2016, Endoscopy.

High titers of anti-infliximab antibody do not interfere with Abbott immunoassays

B. Vásárhelyi, B. Szalay, Z. Végh, 2017, Clinical chemistry and laboratory medicine.

New trends in inflammatory bowel disease epidemiology and disease course in Eastern Europe.

P. Lakatos, Z. Végh, P. Golovics, 2013, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Association of extraintestinal manifestations and anaemia with disease outcomes in patients with inflammatory bowel disease

G. Rogler, S. Vavricka, P. Lakatos, 2016, Scandinavian journal of gastroenterology.

Does Hospitalization Predict the Disease Course in Ulcerative Colitis? Prevalence and Predictors of Hospitalization and Re-Hospitalization in Ulcerative Colitis in a Population-based Inception Cohort (2000-2012).

P. Lakatos, M. Mandel, L. Lakatos, 2015, Journal of gastrointestinal and liver diseases : JGLD.

Prevalence and predictors of hospitalization in Crohn's disease in a prospective population-based inception cohort from 2000-2012.

P. Lakatos, M. Mandel, L. Lakatos, 2015, World journal of gastroenterology.

Decreasing trends in hospitalizations during anti-TNF therapy are associated with time to anti-TNF therapy: Results from two referral centres.

K. Farkas, T. Molnár, P. Lakatos, 2014, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

The risk of lymphoma and immunomodulators in patients with inflammatory bowel diseases: results from a population-based cohort in Eastern Europe.

P. Lakatos, M. Szathmári, M. Mandel, 2013, Journal of Crohn's & colitis.

Is Current Smoking Still an Important Environmental Factor in Inflammatory Bowel Diseases? Results from a Population-based Incident Cohort

P. Lakatos, M. Szathmári, M. Mandel, 2013, Inflammatory bowel diseases.

Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn’s disease

G. Veres, K. Farkas, F. Nagy, 2011, Alimentary pharmacology & therapeutics.

[Predictors of efficacy, mucosal healing and dose intensification during the first year of adalimumab therapy in patients with luminal and fistulizing Crohn's disease. National data from Hungary].

G. Veres, K. Farkas, F. Nagy, 2011, Orvosi Hetilap.

Prediction of Short- and Medium-term Efficacy of Biosimilar Infliximab Therapy. Do Trough Levels and Antidrug Antibody Levels or Clinical And Biochemical Markers Play the More Important Role?

K. Farkas, T. Molnár, M. Papp, 2016, Journal of Crohn's & colitis.

Efficacy of Infliximab Biosimilar CT-P13 Induction Therapy on Mucosal Healing in Ulcerative Colitis.

K. Farkas, F. Nagy, T. Molnár, 2016, Journal of Crohn's & colitis.

Clinical Risk Factors: Lessons from Epidemiology

P. Lakatos, Z. Végh, Z. Kurti, 2019, Biomarkers in Inflammatory Bowel Diseases.

Su1331 Is Hospitalization Predicting the Disease Course in Crohn's Disease? Prevalence and Predictors of Hospitalization and Re-Hospitalization in Crohn's Disease in a Population Based Inception Cohort Between 2000-2012

P. Lakatos, M. Mandel, L. Lakatos, 2014 .

Optimizing biological therapy in Crohn’s disease

P. Lakatos, K. Gecse, Z. Végh, 2016, Expert review of gastroenterology & hepatology.

Long-term Efficacy, Safety, and Immunogenicity of Biosimilar Infliximab After One Year in a Prospective Nationwide Cohort

K. Farkas, F. Nagy, T. Molnár, 2017, Inflammatory bowel diseases.

Branding for business? Hungary and the sustainable development goals

Simon Lightfoot, Z. Végh, Balázs Szent‐Iványi, 2020 .

Is transition experience enough? The donor-side effectiveness of Czech and Polish democracy aid to Georgia

Z. Végh, Balázs Szent‐Iványi, 2018 .

Follow-up of patients with functional bowel symptoms treated with a low FODMAP diet.

P. Munkholm, D. Ankersen, J. Burisch, 2016, World journal of gastroenterology.

Mo1210 Low FODMAP Diet Reduces Irritable Bowel Symptoms and Improves Quality of Life in Patients With Inflammatory Bowel Disease in a Randomized Controlled Trial

D. Ankersen, J. Burisch, N. Pedersen, 2014 .

Sex-Based Differences in Incidence of Inflammatory Bowel Diseases-Pooled Analysis of Population-Based Studies From Western Countries.

S. Ng, G. Kaplan, A. Bitton, 2018, Gastroenterology.

Selectively down-regulated expression of major histocompatibility complex class I alleles in human solid tumors.

E. Klein, Z. Végh, F. Vánky, 1993, Cancer research.

Point mutations in the beta chain CDR3 can alter the T cell receptor recognition pattern on an MHC class I/peptide complex over a broad interface area.

N. Papadopoulos, S. Nathenson, A. Kalergis, 1998, Molecular immunology.

Incidence rates and disease course of paediatric inflammatory bowel diseases in Western Hungary between 1977 and 2011.

G. Veres, P. Lakatos, M. Mandel, 2014, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Red-cell bound anti-A is more efficient than anti-B in competition for fluid phase complement.

G. Tusnády, E. Klein, T. Bakács, 1993, Immunology letters.

Low-FODMAP diet reduces irritable bowel symptoms in patients with inflammatory bowel disease

P. Munkholm, J. R. Andersen, D. Ankersen, 2017, World journal of gastroenterology.

Is early limited surgery associated with a more benign disease course in Crohn's disease?

G. Veres, P. Lakatos, M. Mandel, 2013, World journal of gastroenterology.

eHealth: Individualization of Mesalazine Treatment Through a Self-managed Web-based Solution in Mild-to-moderate Ulcerative Colitis

P. Munkholm, E. Langholz, J. Burisch, 2014, Inflammatory bowel diseases.

Risk of colorectal cancer in Crohn's disease patients with colonic involvement and stenosing disease in a population-based cohort from Hungary.

P. Lakatos, M. Mandel, L. Lakatos, 2013, Journal of gastrointestinal and liver diseases : JGLD.

An in vitro study of the dynamic features of the major histocompatibility complex class I complex relevant to its role as a versatile peptide-receptive molecule.

R. Angeletti, N. Papadopoulos, S. Nathenson, 1997, Proceedings of the National Academy of Sciences of the United States of America.

Efficient T cell activation requires an optimal dwell-time of interaction between the TCR and the pMHC complex

Alexis M. Kalergis, Immanuel F. Luescher, S. Nathenson, 2001, Nature Immunology.

Natural disease course of Crohn’s disease during the first 5 years after diagnosis in a European population-based inception cohort: an Epi-IBD study

V. Andersen, L. Kupčinskas, S. Sebastian, 2018, Gut.

P623 Therapeutic preferences and outcomes in newly diagnosed patient with inflammatory bowel diseases in the biological era in Hungary. A nationwide study based on the National Health Insurance Fund database.

P. Lakatos, K. Gecse, Z. Végh, 2017, Journal of Crohn's & colitis.

Evolution of disease phenotype in adult and pediatric onset Crohn's disease in a population-based cohort.

P. Lakatos, M. Mandel, L. Lakatos, 2013, World journal of gastroenterology.

Cost-effectiveness of biological treatment sequences for fistulising Crohn’s disease across Europe

L. Peyrin-Biroulet, P. Lakatos, S. Danese, 2018, United European gastroenterology journal.

Drug persistence and need for dose intensification to adalimumab therapy; the importance of therapeutic drug monitoring in inflammatory bowel diseases

K. Farkas, T. Molnár, P. Lakatos, 2017, BMC Gastroenterology.

Monoclonal free light chains in urine and their significance in clinical diagnostics: Are they really tumor markers?

S. Ottó, Z. Végh, S. Eckhardt, 1990, Journal of clinical laboratory analysis.

Interactions in the complement-mediated lysis of blood group AB erythrocytes sensitized simultaneously with anti-A and anti-B monoclonal antibodies.

G. Tusnády, Robert B Sim, E. Klein, 1993, Immunology letters.

Editorial: co‐existing immune‐mediated disease in inflammatory bowel diseases – a new disease severity indicator?

P. Lakatos, W. Afif, T. Bessissow, 2017, Alimentary pharmacology & therapeutics.

‘Treat to Target' - Lessons Learnt

P. Lakatos, Z. Végh, P. Golovics, 2016, Digestive Diseases.

High‐sensitivity C‐reactive protein for identification of disease phenotype, active disease, and clinical relapses in Crohn's disease: A marker for patient classification?

M. Papp, P. Lakatos, M. Szathmári, 2012, Inflammatory bowel diseases.

Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases: results from Central European nationwide cohort

K. Farkas, F. Nagy, T. Molnár, 2017, Expert opinion on drug safety.

Natural Disease Course of Ulcerative Colitis During the First Five Years of Follow-up in a European Population-based Inception Cohort—An Epi-IBD Study

V. Andersen, L. Kupčinskas, S. Sebastian, 2018, Journal of Crohn's & colitis.

P694 Disease course during the first five years following diagnosis in a prospective European population-based inception cohort - the ECCO-EpiCom cohort.

L. Kupčinskas, J. Dahlerup, P. Lakatos, 2017, Journal of Crohn's & colitis.

Final Results on Immunogenicity Profile and Predictors of ADA Development of Biosimilar Infliximab During the First 12 Months of the Therapy: Results from a Prospective Nationwide Cohort

K. Farkas, T. Molnár, M. Papp, 2017 .

P592 Final results on immunogenicity profile and predictors of ADA development of biosimilar infliximab during the first 12 months of the therapy: results from a prospective nationwide cohort.

T. Molnár, M. Papp, P. Lakatos, 2017, Journal of Crohn's & colitis.

P331 Final results on efficacy and safety of biosimilar infliximab after one-year: results from a prospective nationwide cohort.

F. Nagy, T. Molnár, M. Papp, 2017, Journal of Crohn's & colitis.

Sa1936 Efficacy and Safety of Biosimilar Infliximab After One-Year: Results From a Prospective Nationwide Cohort

K. Farkas, T. Molnár, P. Lakatos, 2016 .

Real-Life Efficacy, Immunogenicity and Safety of Biosimilar Infliximab

P. Lakatos, Z. Végh, Z. Kurti, 2017, Digestive Diseases.

The incidence of glomerulonephritis in a population-based inception cohort of patients with inflammatory bowel disease.

P. Lakatos, E. Mácsai, L. Lakatos, 2017, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Sa1156 Accelerated Treatment Strategy in Inflammatory Bowel Diseases; Is It Associated With a Change in the Disease Course?

K. Farkas, T. Molnár, M. Papp, 2015 .

Cytotoxic susceptibility and defective MHC class I expression do not correlate with mutation of p53 in human carcinomas

E. Klein, Ping Wang, B. Larsson, 2005, Cancer Immunology, Immunotherapy.

Differences in the competitive capacity of monoclonal antibody sensitized human A and B erythrocytes in complement mediated cytotoxicity.

G. Tusnády, E. Klein, T. Bakács, 1990, Journal of clinical & laboratory immunology.

Hungary’s “Eastern Opening” policy toward Russia: ties that bind?

Z. Végh, 2015 .

Incidence rates and disease course of pediatric inflammatory bowel diseases in western Hungary between 1977 – 2011

G. Veres, P. Lakatos, M. Mandel, 2014 .

Quality of care indicators in inflammatory bowel disease in a tertiary referral center with open access and objective assessment policies.

A. Bitton, P. Lakatos, W. Afif, 2018, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

eHealth: Individualization of Mesalazine Treatment Through a Self-managed Web-based Solution in Mild-to-moderate Ulcerative Colitis

P. Munkholm, E. Langholz, J. Burisch, 2014, Inflammatory bowel diseases.

Visegrad development aid in the Eastern Partnership Region. OSW Report, February 2014

Z. Végh, 2014 .